EUROAPI (Euronext Paris:EAPI), a provider of active pharmaceutical ingredients, announced on Tuesday that it has signed a five-year Contract Development and Manufacturing Organisation (CDMO) agreement with Priothera, a blood cancer treatment specialist.

Under this agreement EUROAPI will develop and industrialise the production process for mocravimod, Priothera's innovative therapy for blood cancers, at its Budapest facility.

Mocravimod is a S1P receptor modulator being developed to reduce relapse rates and improve patient survival in blood cancers. It has been granted Orphan Drug designation by regulators in Europe and the United States.

This collaboration strengthens EUROAPI's position in the growing oncology market, which is projected to reach USD375bn by 2027.